Genmab — September 2020

[E_L]

it is a repeat of the ASCO data

[gentogen]

Using health care claims databases, our analysis indicates that the adjusted (unadjusted) prevalence of AL amyloidosis increased significantly from 20.1 (15.5) cases per million in 2007 to 50.1 (40.5) cases per million in 2015, an annual percentage change of 12% (11.9%)

[gentogen]

Extrapolating from these data, there were at least 12 000 adults in the United States living with AL amyloidosis in 2015

[gentogen]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965052/

[gentogen]

So this is very good news for patients

[E_L]

Genmab

annual report p 26 -3,000-4,000 approximate number of new cases diagnosed annually, making AL amyloidosis the most common type of amyloidosis in the U.S - An estimated 16,000 people in the United States suffer from amyloidosis. - 12-15% of multiple myeloma patients develop light chain (AL) amyloidosis.

[E_L]

The problem with amyloidosis is that it is often not recognised immediatley as amyloidosis ; it often comes through other doctors after hearth or renal failure if i understand correctly

[E_L]

i am sure an awareness campaign will be part of the JNJ marketing strategy . There are probably more -unidentified- patients with amyloidosis

[E_L]

Building on BCMA-Directed Therapies in Multiple Myeloma https://www.onclive.com/view/building-on-bcma-directed-therapies-in-multiple-myeloma

[Sukkeralf]

Ocrevus

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Legolas23]

Nice one

[E_L]

Trispecific antibodies take to the clinic -mentions the Sanofi CD3xCD28xCD38 - https://www.nature.com/articles/d41573-020-00164-3

[Sukkeralf]

Paul Parren, CEO of the γδ T cell-engaging bispecific company Lava Therapeutics, is watching this space. “I like bispecifics a lot, and I also like trispecifics a lot,” he says

[Sukkeralf]

Old Genmab guy

[E_L]

yes, and his name still regularly
shows up in publications together with Genmab researchers

[Sukkeralf]

Jep - if Lave Therapeutics goes to market I think I would throw some money after PP

[E_L]

traitor

[E_L]

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis https://www.novartis.com/news/media-releases/novartis-presents-data-actrims-ectrims-kesimpta-ofatumumab-newly-diagnosed-treatment-naive-adults-relapsing-multiple-sclerosis

[Klarussen]

Genmab begynder at vise svaghedstegn

Kommentarerne til C25-aktierne er primært baseret på teknisk analyse med en tidshorisont på 2-3 uger og ikke dybdegående fundamentalanalyser. Købs- og salgsanbefalingerne er kun vejledende. A. P. Møller – Mærsk A – Hold Aktuel kurs: 8875,00 A. P. Møller – Mærsk A følger stort set selskabets B-aktie, og giver derfor ikke anledning til en selvstændig […]

Økonomisk Ugebrev (ugebrev.dk)